Skip to main content
Premium Trial:

Request an Annual Quote

Tm Biosciences Closes $CA12M Private Placement

NEW YORK, Dec. 22 (GenomeWeb News) - Tm Biosciences of Toronto said today it had closed a $CA12 million ($9 million) private placement


In this placement, the publicly traded company sold 37.5 million shares at $CA.32 per unit, which includes a common share in the capital of the company and a purchase warrant for a half of a common share that can be exercised at the price of $CA.40 per share through June 2005. The $CA12 million figure represented the gross proceeds.


The company said the financing would be used for further development and commercialization of the company's genetic tests, which are based on its Tm 100 platform.


The company recently received a $CA 7.3 million investment from Technology Partnerships Canada, a Canadian government funding agency.


"The proceeds of this financing, together with the recently announced $7.3 million investment from Technology Partnerships Canada (TPC), provide Tm with the financial security to move into profitability," Greg Hines, President and CEO of Tm Bioscience, said in a statement.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.